BNT162b2 Vaccine Booster and Mortality | NEJM

75. 코로나 백신 부스터샷이 필요한 이유(2021.12월 NEJM 논문 분석)Подробнее

Omicron-Containing Covid-19 Vaccine | NEJMПодробнее

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine | NEJMПодробнее

BNT162b2 Covid-19 Vaccine in 5-to-11-Year-Olds | NEJMПодробнее

Vaccine Efficacy and Boosters in Covid-19Подробнее

Vaccine for COVID-19 | NEW Paper NEJM with Phase I Clinical Trial for mRNA-1273 Coronavirus VaccineПодробнее

A New Look at Covid-19 Vaccine BoostersПодробнее

Effectiveness of Covid-19 Vaccine in Adolescents | NEJMПодробнее

mRNA Covid-19 Vaccination in U.S. Health Care Personnel | NEJMПодробнее

Effectiveness of COVID-19 Vaccines Against the B.1.617.2 Variant of ConcernПодробнее

NEJM Interview: Dr. Dan Barouch on researchers' ongoing quest to develop an HIV-1 vaccine.Подробнее

VV116 for Oral Treatment of Covid-19 | NEJMПодробнее

Safety and Efficacy of the BNT162b2 Covid 19 VaccineПодробнее

One vaccine dose and two viral variantsПодробнее

Monoclonal Antibodies and Vaccine BoostsПодробнее

When to Get a Second Covid-19 Booster ShotПодробнее

Vaccines Update, NEJM Weighs InПодробнее

Monoclonal Antibodies and Booster ShotsПодробнее

Short-term effects of BNT162b2 mRNA COVID-19 vaccination on physiological markersПодробнее